1. In Vivo
  2. >>Deal-Making

Bard EP Deal Latest In Boston Scientific’s M&A Revival, Bolsters CRM Business

Boston Scientific’s recent acquisition of Bard Electrophysiology marks the tenth notable acquisition that it has made since 2010. Four of those deals come in cardiac rhythm management, including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth.

After sitting on the dealmaking sidelines just a few years ago while trying to figure out how to digest its $27 billion acquisition of Guidant Corp. in 2005, Boston Scientific Corp. is back in the M&A game, which is welcome news to device start-ups worldwide. [See Deal] Its recent acquisition of Bard Electrophysiology (EP), a division of CR Bard Inc., marks the tenth notable acquisition that Boston Scientific has made since 2010. Four of those deals come in cardiac rhythm management (CRM), including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth. [See Deal]

Throughout the early 2000s, Boston Scientific was one of the most aggressive strategic acquirers, pioneering the practice of taking small equity stakes in numerous start-ups through structured deals tied to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.